Executive Director, Clinical Research and Clinical Science and Program Leadership SER-287 and SER-301
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres' clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI.
Passionate and innovative oncology research scientist and clinical project lead, with extensive background in genetics and molecular cell biology. Award-winning leader in community and student STEM (science, technology, engineering, mathematics) education and CSR (corporate social responsibility).
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of David Lichter at Seres Therapeutics then you've come to the right place.
Wondering if it's david@serestherapeutics.com, david.lichter@serestherapeutics.com, lichter@serestherapeutics.com, or dlichter@serestherapeutics.com? We have the answers for you.